(USD) | Jun 2023 | Q/Q |
---|---|---|
Revenue | 344MM | -82% |
Gross Profit | -387MM | - |
Cost Of Revenue | 731MM | -8% |
Operating Income | -1.9B | - |
Operating Expenses | 1.5B | - |
Net Income | -1.4B | -1847% |
R&D | 1.1B | +2% |
G&A | 332MM | +9% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Moderna stock is under pressure and estimates have come down for its first quarter. Is MRNA stock now a sell?
China's vaccine developers stuck with unused mRNA COVID shots and idle manufacturing plants are pursuing new targets for the novel messenger RNA technology, but they face a tough path, crimped by a lack of revenue. Three Chinese companies - Walvax Biotechnology, CSPC Pharmaceutical Group and Stemirna Therapeutics - came up with mRNA vaccines that won limited emergency approvals in Asia. However, Walvax and CSPC are not currently manufacturing three of their China market shots, a China health o...
In the latest trading session, Moderna (MRNA) closed at $103.44, marking a -0.34% move from the previous day.
Brad Miller is helping Moderna shift from its reliance on COVID vaccines, with the company hoping to introduce up to 15 new drugs over a five-year period.
CAMBRIDGE, MA / ACCESSWIRE / April 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 2, 2024 to report its first quarter 2024 financial results, and provide ...
On Tuesday, Johnson & Johnson (NYSE: JNJ) delivered a rather mixed first quarter report. Adjusted earnings surpassed estimates as sales in its medical devices business surged, while revenue was almost in line with estimates. First quarter results came shortly after JNJ’s expansion in the cardiovascular space with the $13.1 billion acquisition of heart device firm Shockwave Medical Inc (NASDAQ: SWAV). First Quarter Highlights For the period ended in March, the healthcare company posted a revenue
Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
These companies have gotten in on AI early and could emerge as winners.
These stocks have plenty of catalysts ahead.
For many, the main point of investing in the stock market is to achieve spectacular returns. While not every stock...